Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)

  • STATUS
    Recruiting
  • End date
    Dec 31, 2028
  • participants needed
    45
  • sponsor
    Beth Israel Deaconess Medical Center
Send
Updated on 9 August 2022
See if I qualify
aortic aneurysm
aneurysm repair
malignancy

Summary

The primary objective of this study is to examine the safety and effectiveness of physician-modified endovascular grafts (PMEGs) for endovascular repair of complex aortic pathology in high-risk patients. The study is divided into three study arms based on the subject's aortic pathology: (1) Complex abdominal aortic aneurysm (AAA); (2) Thoracoabdominal aortic aneurysm; and (3) Aortic dissection.

Description

Complex aortic pathology, comprised of aneurysmal disease and aortic dissection involving the visceral aortic segment, presents a technical challenge for repair due to involvement of the renal and/or mesenteric arteries. Traditionally, the gold standard for repair has been open repair. However, open repair of these diseases is associated with high perioperative morbidity and mortality. Therefore, for patients with significant medical comorbidities or complex surgical/anatomical features, the risk of open surgery may be prohibitive.

As endovascular techniques have become increasingly advanced, options for the endovascular treatment of complex aortic pathology involving the visceral segment have been developed. The predominant approach is fenestrated or branched endovascular aortic repair (F/B-EVAR) with fenestrated or branched endovascular grafts. Currently, there is only one device FDA-approved for commercial use in the United States, the Zenith Fenestrated AAA Endovascular Graft (Cook Medical, Bloomington, IN). However, its use is limited by the design specifications of the device and the required manufacturing time in patients requiring more urgent repair. Therefore, many patients with complex aortic pathology are not eligible for repair with this device, and there are currently no other FDA-approved options for definitive repair.

One option for definitive repair of complex aortic pathology in patients ineligible for the Zenith fenestrated device is endovascular repair with a physician-modified endovascular graft (PMEG). For this procedure, the operating surgeon modifies an FDA-approved endovascular graft to incorporate fenestrations or branches based on the patient's anatomy. Numerous reports have been published demonstrating that this procedure can be performed with high technical success, and acceptable perioperative and mid-term results in high-risk patients.

The primary objective of the study is to evaluate safety and effectiveness of PMEGs for the endovascular repair of complex aortic pathology in high-risk patients. The safety outcomes include perioperative mortality (defined as death <30 days postoperative or during the index hospitalization) and major adverse events, along with mortality and adverse events during follow-up. Effectiveness outcomes include initial technical success, endoleak rate, target vessel patency, and rate of reintervention. Patients will be followed for five years. Patients will be evaluated preoperatively, at the time of the procedure, at the time of discharge from the index hospitalization, 1-month post-procedure, 6-months post-procedure, and 1-year post-procedure, and annually for five-years.

Details
Condition Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Dissection
Treatment Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Clinical Study IdentifierNCT04746677
SponsorBeth Israel Deaconess Medical Center
Last Modified on9 August 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

General inclusion criteria (applicable to all 3 study arms)
Aortic pathology that fits one of the study arms (see below for detailed description)
Aortic pathology that cannot be treated within the Instructions for Use of an FDAapproved, commercially-available device
Aortic aneurysm that can be treated within the Instructions for Use of an FDA-approved, commercially-available custom-manufactured device but deemed unsafe to wait the required time for device manufacturing
Subject is at high-risk of morbidity and mortality with open surgical repair based on cardiopulmonary function, extent of comorbid disease, and anatomic complexity
Iliac and/or femoral access vessel morphology that is compatible with vascular access techniques, devices, or accessories, with or without use of a surgical or endovascular conduit
Non-aneurysmal aortic segment proximal to the aortic pathology with a
Minimum neck length of 20 mm
Diameter between 20 - 42 mm
Non-aneurysmal aortic or iliac segment distal to the aortic pathology with
Aortic distal fixation site greater than 20 mm in length and diameter between 20-42 mm
Iliac artery distal fixation site greater than 10 mm in length and diameter range 8- 25 mm
Age ≥21 years old
Life expectancy: ≥2 years
Arm1
Complex abdominal aortic aneurysm, specifically juxtarenal or suprarenal abdominal
Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease extending above the diaphragmatic hiatus
aortic aneurysm or type IV thoracoabdominal aortic aneurysm, with maximum
Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease above the diaphragmatic hiatus
diameter of ≥5.5 cm for men or ≥5.0 cm for women, growth ≥0.5 cm in 6 months
or concomitant iliac aneurysm ≥3 cm
Saccular complex abdominal aortic aneurysm deemed at significant risk for rupture
Symptomatic complex aortic aneurysm
Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus
Arm2
Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus
Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair with aneurysmal disease extending above the diaphragmatic hiatus
Prior thoracic endovascular aneurysm repair with loss of distal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair
Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, with aneurysmal disease above the diaphragmatic hiatus
Type I, II, or III thoracoabdominal aortic aneurysm with maximum diameter of ≥5.5 cm
Saccular type I, II, or III thoracoabdominal aortic aneurysm deemed at significant risk for rupture
or growth ≥0.5 cm in 6 months
Symptomatic type I, II, or III thoracoabdominal aortic aneurysm
Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus
Arm 3
Acute or chronic type B aortic dissection with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or persistence of symptoms despite optimal medical therapy
Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus
Prior repair of type A dissection and development of acute or chronic type B dissection component with indication for repair (listed above)
Aortic intramural hematoma (IMH) with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or more typically, persistence of symptoms despite optimal medical therapy

Exclusion Criteria

General Exclusion Criteria
Subject is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
Subject is unwilling to comply with the follow-up schedule
Inability or refusal to give informed consent by subject or legal representative
Subject is pregnant or breastfeeding
Subject has a ruptured aneurysm
Medical Exclusion Criteria
Known sensitivities or allergies to the materials of construction of the devices
Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
Uncorrectable coagulopathy
Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
Systemic or local infection that may increase the risk of endovascular graft infection
Diagnosis of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)
Anatomic Exclusion Criteria
Inability to perform open or endovascular iliac conduit in patients with inadequate femoral/iliac access
Excessive thrombus or calcification within the neck of the aneurysm
Visceral vessel anatomy not compatible with placement of a physician-modified endovascular graft due to occlusive disease or small size
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

aortic aneurysm
aneurysm repair
malignancy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note